A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism

Last updated: December 9, 2024
Sponsor: Ultimate International, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metabolic Disorders

Treatment

Placebo Capsule

Diaberine

Clinical Study ID

NCT06700915
20442
  • Ages 18-70
  • All Genders

Study Summary

This randomized, triple-blind, placebo-controlled study will evaluate the efficacy of Diaberine, a berberine-based nutraceutical, in aiding blood sugar regulation and metabolism in 80 participants over 24 weeks.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female.

  • BMI: 27-35 kg/m2

  • HbA1c of 5.7%-6.4% (determined by prescreening blood test)

  • Be generally healthy

  • Willing to refrain from taking any products, prescription medications, orsupplements that target blood sugar regulation or metabolism during the test period.

  • Willing to maintain their current diet, sleep schedule, and activity level for theduration of the study.

Exclusion

Exclusion Criteria:

  • Diagnosed with Type 2 diabetes mellitus (T2DM) and have been prescribed metformin,insulin, Sulfonylureas, Meglitinides, SGLT2 inhibitors and/or GLP-1 medicationsincluding the following prescription medications: Wegovy (semaglutide), Ozempic (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide), Victoza (liraglutide),Zepbound (bimagrumab), Byetta (exenatide), Bydureon (exenatide ER), Trulicity (dulaglutide), Adlyxin (lixisenatide)

  • Current use or past history of use within the last 2 months (8 weeks) of thefollowing prescription medications: Beta-blockers Sectral (Acebutolol), Tenormin (Atenolol), Kerlone, Betoptic (Betaxolol), Zebeta (Bisoprolol), Coreg, Coreg CR (Carvedilol), Trandate, Normodyne (Labetalol), Lopressor, Toprol XL (Metoprolol),Corgard (Nadolol), Bystolic (Nebivolol), Levatol (Penbutolol), Visken (Pindolol),Inderal, Inderal LA, InnoPran XL (Propranolol). Thiazide diuretics Diuril (Chlorothiazide), Microzide (Hydrochlorothiazide), Thalitone, Hygroton (Chlorthalidone), Lozol (Indapamide), Zaroxolyn (Metolazone), Naturetin (Bendroflumethiazide), Enduron (Methyclothiazide). Corticosteroids Deltasone (Prednisone), Orapred, Prelone (Prednisolone), Medrol (Methylprednisolone), Qvar (Beclomethasone), Celestone (Betamethasone), Decadron (Dexamethasone), Cortef (Hydrocortisone), Kenalog (Triamcinolone). Immunosuppressants Tacrolimus (Prograf),Cyclosporine (Neoral), Sirolimus (Rapamune)

  • Women who are pregnant, breastfeeding, or trying to conceive.

  • Anyone unwilling or unable to follow the study protocol.

  • Any pre-existing chronic conditions that would prevent participants from adhering tothe protocol, including oncological and psychiatric disorders.

  • Is currently undergoing or planning to undergo any significant medical procedures inthe next six months

  • Has had any major illness in the last three months.

  • A history of severe allergic reactions, including but not limited to any of theproduct's ingredients.

  • Heavy drinkers or drug users. A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinksper week.

  • Impaired hepatic function.

  • Individuals taking prescription or over-the-counter medication, or herbal remediesthat affect blood sugar regulation or metabolism.

  • Currently being treated for an infection with an antibiotic and/or antiviralprescription medication.

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Placebo Capsule
Phase:
Study Start date:
October 03, 2024
Estimated Completion Date:
May 01, 2025

Connect with a study center

  • Citruslabs

    Santa Monica, California 90404
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.